Review



caski  (Pasteur Institute)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pasteur Institute caski
    Caski, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caski/pm42113498-41-15-27?v=Pasteur+Institute
    Average 86 stars, based on 1 article reviews
    caski - by Bioz Stars, 2026-08
    86/100 stars

    Images



    Similar Products

    caski  (ATCC)
    97
    ATCC caski
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). <t>(E)</t> <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Caski, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caski/pmc13092703-47-4-5?v=ATCC
    Average 97 stars, based on 1 article reviews
    caski - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    cervical cancer cell lines caski  (ATCC)
    98
    ATCC cervical cancer cell lines caski
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). <t>(E)</t> <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Cervical Cancer Cell Lines Caski, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caski/pm42172712-51-2-25?v=ATCC
    Average 98 stars, based on 1 article reviews
    cervical cancer cell lines caski - by Bioz Stars, 2026-08
    98/100 stars
    		  Buy from Supplier
    caski  (Pasteur Institute)
    86
    Pasteur Institute caski
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). <t>(E)</t> <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Caski, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caski/pm42113498-41-15-27?v=Pasteur+Institute
    Average 86 stars, based on 1 article reviews
    caski - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    caski cervical epidermoid carcinoma  (ATCC)
    97
    ATCC caski cervical epidermoid carcinoma
    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) <t>CaSki</t> cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). <t>(E)</t> <t>SiHa</t> ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.
    Caski Cervical Epidermoid Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caski/us12600793-830-80-84?v=ATCC
    Average 97 stars, based on 1 article reviews
    caski cervical epidermoid carcinoma - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

    doi: 10.1016/j.neo.2026.101305

    Figure Lengend Snippet: Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. ( A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5uM BYL-719, washed at 24 h and place in 0, 1 or 5uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa ( PIK3CA WT) shows no reduction ofHPV16 E7 after treatment with BYL-719 (exposure time, 3 min). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719. (G) SiHa cells treated with BYL719. *=P < 0.05, **=P < 0.01, ***=P < 0.001.

    Article Snippet: CC cell lines, including CaSki (ATCC Cat# CRM-CRL-1550_Ca Ski, RRID: CVCL_1100), SiHa (ATCC Cat# HTB-35_SiHa, RRID: CVCL_0032), and ME180 (ATCC Cat# HTB-33_ME-180, RRID: CVCL_1401), C33A (ATCC CRM-HTB-31, RRID:CVCL_1094) were obtained from ATCC.

    Techniques: Expressing